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ATR and CHK1 maintain cancer cell survival under
replication stress and inhibitors of both kinases are
currently undergoing clinical trials. As ATR activity
is increased after CHK1 inhibition, we hypothesized
that this may indicate an increased reliance on
ATR for survival. Indeed, we observe that replica-
tion stress induced by the CHK1 inhibitor AZD7762
results in replication catastrophe and apoptosis,
when combinedwith the ATR inhibitor VE-821 specif-
ically in cancer cells. Combined treatment with ATR
and CHK1 inhibitors leads to replication fork arrest,
ssDNA accumulation, replication collapse, and syn-
ergistic cell death in cancer cells in vitro and in vivo.
Inhibition of CDK reversed replication stress and
synthetic lethality, demonstrating that regulation of
origin firing by ATR and CHK1 explains the synthetic
lethality. In conclusion, this study exemplifies can-
cer-specific synthetic lethality between two proteins
in the same pathway and raises the prospect of
combining ATR and CHK1 inhibitors as promising
cancer therapy.
INTRODUCTION
Cancer is a disease of uncontrolled cellular proliferation, driven
by oncogenes, leading to unfaithful and uncoordinated DNA
replication, genomic instability, and DNA double-strand breaks
(DSBs) (Alexandrov et al., 2013; Bartkova et al., 2006; Di Micco
et al., 2006). DSBs activate the ATM kinase, which in turn medi-
ates p53-dependent cell-cycle arrest and apoptosis, working as
a tumor barrier to cancer development (Bartkova et al., 2005;
Gorgoulis et al., 2005; Halazonetis et al., 2008). In contrast, the
ATR kinase is activated by single-stranded DNA (ssDNA) present
at stalled replication forks (Hekmat-Nejad et al., 2000; Zou and
Elledge, 2003). ATR phosphorylates the checkpoint kinase
CHK1, which plays a crucial role in preventing origin firing (Feijoo
et al., 2001), avoiding premature chromosome condensation and298 Cell Reports 14, 298–309, January 12, 2016 ª2016 The Authorsfacilitating RAD51-mediated homologus recombination (Cim-
prich and Cortez, 2008; Sørensen et al., 2005).
Since cancer cells often harbor some degree of replication
stress, they upregulate ATR and CHK1 activity to mediate sur-
vival (Choi et al., 2011; Toledo et al., 2011). For example, B cell
lymphomas are sensitive to CHK1 inhibitors as they have a
high degree of MYC-induced replication stress (Ho¨glund et al.,
2011; Murga et al., 2011). Cancer cells also commonly lack
compensatory DNA damage response proteins that are syn-
thetic lethal with the ATR pathway, including ATM and p53
(Ding et al., 2008; Jiang et al., 2009), which further increases reli-
ance on ATR and CHK1 in damaged tumor cells (Choi et al.,
2011; Murga et al., 2009; Reaper et al., 2011). In addition, the
cytotoxic mechanism of action of many anti-cancer drugs is
to induce replication stress and replication-associated DNA
damage. Taken together, ATR or CHK1 inhibition is a promising
strategy, and selective inhibitors are undergoing clinical trials in
combination with DNA-damaging chemotherapy and ionizing ra-
diation (Brooks et al., 2013; Fokas et al., 2012; Foote et al., 2013,
2015; Josse´ et al., 2014; Ma et al., 2011; Mitchell et al., 2010;
Tang et al., 2012).
Although the ATR and CHK1 kinases function in the same
pathway, they also may exert unique functions. For example,
the ATR protein appears to have a more important role than
CHK1 in preventing replication collapse after UV damage
(Elvers et al., 2012), which is likely related to a unique role of
ATR in supplying RPA to protect replication forks (Toledo
et al., 2013). We and others previously have found that inhibition
or depletion of CHK1 causes replication stress and activation of
ATR, which is explained by the role of CHK1 in suppressing
replication origin firing (Choi et al., 2011; Gagou et al., 2010;
Petermann et al., 2010a; Syljua˚sen et al., 2005). Since ATR is
critical for replication fork stability under conditions of replica-
tion stress (Toledo et al., 2013), which may be independent of
CHK1 (Elvers et al., 2012), we hypothesized that ATR may be
critical for survival upon CHK1 inhibition in cancer cells. In line
with this hypothesis, we demonstrate that sub-toxic concentra-
tions of both the ATR inhibitor VE-821 and the CHK1 inhibitor
AZD7762 combine synergistically to induce complete replica-
tion collapse and apoptosis specifically in cancer cells. In addi-
tion, the combination of the ATR inhibitor VX-970 and AZD7762
markedly improves overall survival in mice bearing lung and
breast tumor xenografts at well-tolerated doses. Here we
show cancer-specific synthetic lethality using ATR and CHK1
inhibitors in combination. These data demonstrate that syn-
thetic lethality can be obtained by targeting proteins within the
same pathway, and they provide compelling evidence that the
combination of ATR and CHK1 inhibitors may be used as a
promising cancer therapy.
RESULTS
Combined ATR and CHK1 Inhibition Induces Excess
ssDNA, JNK-Mediated Pan-nuclear gH2AX, and DNA
Damage in Cancer Cells
In our previous study, we demonstrated that the inhibition of
CHK1 using the small molecules UCN-01 and CEP-3891 or
depletion of CHK1 by small interfering RNA (siRNA) results
in increased initiation of DNA synthesis and phosphoryla-
tion of ATR substrates (Syljua˚sen et al., 2005). Likewise, the
CHK1 inhibitor AZD7762 also causes phosphorylation of
CHK1 (a marker for ATR activation), which gets suppressed
by ATR inhibitor VE-821 (Figures 1A and 1D). We found that
these phosphorylation events are dependent on ATR activity,
not on other kinases like ATM or DNAPK, as only selective
ATR inhibitors VE-821 and VX-970 decrease phosphorylation
of CHK1 on Ser345 (Figures 1A and S1A–S1D). Taken
together, our current and previously published data on
VE-821 and AZD7762 show that the doses used in this
study result in nearly complete inhibition of ATR signaling
by VE-821 and VX-970 (Figures S1A–S1C; Huntoon et al.,
2013; Josse´ et al., 2014; Reaper et al., 2011) and CHK1
signaling by AZD7762 (Aris and Pommier, 2012; Zabludoff
et al., 2008).
Although no significant increase in gH2AX foci or pan-nuclear
gH2AX (a marker of widespread replication fork collapse) was
observed in cells treated with VE-821 or AZD7762 alone for
24 hr, the combined treatment triggered a dose-dependent in-
duction of pan-nuclear gH2AX in U2OS cells (Figures 1B–1D,
S2A, and S2B). Interestingly, all the pan-nuclear gH2AX-positive
cells were completely devoid of nuclear 53BP1 foci, indicating
irreparable DNA damage. We observed a decrease in S10H3
phosphorylation (marker for mitosis) and a marked increase in
gH2AX (DNA damage marker) in U2OS cells treated with the
combination of VE-821 and AZD7762, but not in cells treated
with either inhibitor alone. This suggests that either ATR or
CHK1 inhibitor alone exhibits its effect by abrogating the cell-cy-
cle checkpoint leading to mitotic catastrophe, while combining
both results in extensive DNA damage that likely leads to replica-
tion catastrophe (Figure 1D).
To directly determine the magnitude of the DNA damage, we
used an alkaline comet assay. Only the combination of both
drugs significantly induced DNA breaks (Figures 1E, 1F, S2C,
and S2D), with a similar proportion of cells affected as were pos-
itive for pan-nuclear gH2AX. In contrast to U2OS cells, there was
no significant induction of pan-nuclear gH2AX and nuclear
53BP1 in VH-10 normal fibroblasts (Figures S2E–S2G). This sug-
gests that the combination of VE-821 and AZD7762 specifically
induces replication fork collapse in cancer cells.CCHK1 inhibition in cells initiates excessive origin firing, replica-
tion fork stalling, and ssDNA formation (Syljua˚sen et al., 2005;
Wilsker et al., 2008). ssDNA is protected by the ssDNA-binding
protein RPA, which subsequently activates ATR (Nam and Cor-
tez, 2011; Toledo et al., 2013). We analyzed pre-extracted
RPA32 foci formation in U2OS cancer and VH-10 primary cells.
There was no statistically significant increase in the RPA-positive
cell population when U2OS cells were treated with AZD7762
alone at 30 nM for 24 hr in comparison to DMSO control, while
treatment with 60 nM or 10 mM VE-821 significantly increased
the RPA-positive cell population (Figure 1G). As expected the
combination of AZD7762 (30 or 60 nM) and 10 mM VE-821 for
24 hr caused a large increase in the RPA-positive U2OS cell
population (Figure 1G). In contrast to U2OS cells, treatment of
VH-10 cells with AZD7762 and VE-821 alone or in combination
only marginally increased the RPA-positive cell population
(Figure 1H). These results suggest that replication stress was
specifically induced by the combination of ATR and CHK1 inhib-
itors in U2OS cancer cells, but not normal cells. The differential
response between cancer cells and normal cells cannot be ex-
plained by slower proliferation of the VH-10 cells, as virtually all
cells had progressed through the cell cycle within the 24-hr treat-
ment period (Figures S3A and S3B).
UVA-induced pan-nuclear gH2AX in normal fibroblasts is
known to be mediated by JNK and ATM (de Feraudy et al.,
2010) kinases. We used small molecule JNK (SR-3306) and
ATM (KU-55933) inhibitors to investigate if the pan-nuclear
gH2AX induced by combined ATR and CHK1 inhibition also is
mediated by the same pathway. The JNK inhibitor markedly
reduced the pan-nuclear gH2AX-positive cell population after
24-hr treatment with VE-821, AZD7762, or the combination,
while the ATM inhibitor had only a minor effect under all condi-
tions (Figure 1I). Conversely, while the JNK inhibitor increased
the proportion of cells positive for discrete gH2AX foci (a marker
of lower levels of DNA damage), this form of H2AX phosphoryla-
tion was fully ablated by ATM inhibition (Figure 1I). These data
suggest distinct roles for ATM and JNK in the cellular response
to combined inhibition of ATR and CHK1.
ATR and CHK1 Inhibitors Are Synthetic Lethal
Selectively in Cancer Cells
The induction of pan-nuclear gH2AX is suggestive of high levels
of replication stress (Choi et al., 2011). We therefore asked
whether dual inhibition of ATR and CHK1 is sufficient to trigger
cancer cell death. Clonogenic survival assays were performed
on U2OS, MCF-7 cancer, and VH-10 primary cells treated with
a range of concentrations of VE-821 with and without 20 nM
AZD7762. AZD7762 clearly potentiated the effect of VE-821 in
U2OS and MCF-7 cancer cells (3- to 10-fold shifts in the IC50 of
VE-821), but not in the normal VH-10 fibroblast cells (Figure 2A).
Notably, we observed similar growth kinetics across the lines
without treatment, indicating that proliferation rate alone does
not account for this cancer-specific effect (FiguresS3AandS3B).
Cancer cells often have elevated levels of oncogene-induced
replication stress (Hills and Diffley, 2014), requiring the ATR/
CHK1 pathway to prevent cell death (Gabay et al., 2014; Murga
et al., 2011; Rohban and Campaner, 2015). To investigate the
role of oncogene-induced replication stress in the selectiveell Reports 14, 298–309, January 12, 2016 ª2016 The Authors 299
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Figure 1. ATR Target Activation by the
CHK1 Inhibitor AZD7762 in U2OS Cancer
Cells
(A) Western blot showing activation of ATR targets.
U2OS cells were treated with the indicated con-
centrations for 30 and 60 min, lysed, and probed
with anti-phospho (Serine 345) CHK1 and b-actin
antibodies.
(B) Induction of pre-apoptotic pan-nuclear g-H2AX
by ATR and CHK1 inhibitor in combination in
cancer cells. U2OS cells were treated with the
indicated drug concentrations for 24 hr. Cells were
probed with anti-phospho (Serine 139) H2AX
antibody. Scale bar, 20 mm.
(C) Quantitative data of gH2AX- (nine or more foci
per cells) positive cells or pan-nuclear gH2AX
signal after indicated treatments are shown (n = 3,
mean ± SEM).
(D) Western blot showing increased phosphoryla-
tion of H2AX after combination treatment. U2OS
cells were treated with the indicated concentra-
tions for 24 hr. At the end of incubation time,
western blotting was performed using anti-
phospho (Serine 139) H2AX, anti-phospho (Serine
345) CHK1, cleaved PARP, anti-phospho (Serine
10) H3, and b-actin antibodies.
(E) Comet assay showing DNA damage induction
by ATR and CHK1 inhibitor in combination. U2OS
cells were treated with the indicated drug con-
centrations for 24 hr. At the end of incubation, cells
were harvested and alkaline comet assay was
performed.
(F) Quantitative data of the tail moment are shown
(n = 3, mean ± SEM, in each experiment R100
comets were measured).
(G) Cancer-specific ssDNA formation by VE-821
and AZD7762, either alone or in combination.
U2OS cells were treated with the indicated drug
concentrations for 24 hr and pre-extracted using
CSK buffer before fixation. Cells were stained with
anti-RPA32 antibody; images were taken using a
confocal microscope and were analyzed using
ImageJ software. A mean intensity ofR70 a.u. per
cell was considered as positive. Quantitative data
are presented as mean ± SEM from three inde-
pendent experiments.
(H) ssDNA formation in normal fibroblast VH-10
cells is shown.
(I) Pre-apoptotic pan-nuclear gH2AX induction by
combination treatment of ATR andCHK1 inhibitors
in U2OS is mediated through the JNK pathway. U2OS cells were treated with the indicated drug concentrations for 24 hr. Cells were probed with anti-phospho
(Serine 139) H2AX antibody, and high-throughput microscopywas used to determine the percentage of gH2AX-positive cells (nine or more gH2AX foci per cell) or
an average intensity ofR2,000 a.u. for pan-nuclear gH2AX-positive cells (n = 2 with multiple wells, mean ± SEM). Statistical significance was determined using
one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).anti-cancer effect of combined ATR and CHK1 inhibition, we
compared theeffectsof this treatment in transformedcMYC-over-
expressing cells (HA1EB-GFP-cMYC) versus isogenic non-trans-
formed control cells (HA1EB-GFP). cMYC is a proto-oncogene
that frequently is upregulated in cancer and acts as a regulator
of multiple biological processes, including cell growth, cell-cycle
progression, andapoptosis (Gabayet al., 2014;RohbanandCam-
paner, 2015). HA1EB-GFP-cMYC cells have a higher replicative
rate and higher levels of DNA damage than control cells, as ex-
pected from cMYC overexpression (Figures S3C–S3F). HA1EB-300 Cell Reports 14, 298–309, January 12, 2016 ª2016 The AuthorsGFP and HA1EB-GFP-cMYC cells were treated with VE-821 and
AZD7762 either alone or in combination for 72 hr. We found that
30 nM AZD7762 markedly sensitized cMYC-transformed cells,
but not the control cells, to VE-821 (Figure 2B).
To extend these observations, we analyzed the effects of dual
ATR and CHK1 inhibition in non-transformed BJ cells immortal-
ized with hTERT compared with transformed isogenic lines addi-
tionally expressing SV40 large T antigen (that inactivates p53
and RB) and H-RAS V12 (Hahn et al., 1999; Figure S3G). In
agreement with previous results, we observed synthetic lethality
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Figure 2. Combination of the ATR Inhibitor VE-821 and the CHK1 Inhibitor AZD7762 Synergistically Kills Cancer Cells
(A) Clonogenic survival of U2OS, VH-10, and MCF-7 cells. The 500 (U2OS and MCF-7) or 1,000 (VH-10) cells were seeded in 10-cm2 dishes, and, after 5-hr
incubation, the inhibitors were added directly to the media. After 72-hr incubation, drug-containing media were replaced with fresh media and cells were kept for
another 5–8 days before colonies were stained with methylene blue. Quantitative data: n = 3, mean ± SEM.
(B) Parental and cMYC-transformed cells were treatedwith the indicated doses for 72 hr. At the end of the incubation period, resazurin was added and cell viability
was measured. Quantitative data: n = 3, mean ± SEM.
(C) BJ-hTERT, BJ-hTERT SV40, and BJ SV40 RAS cells were treated with the indicated doses for 72 hr. At the end of the incubation period, resazurin was added
and cell viability was measured. Quantitative data: n = 3, mean ± SEM.
(D) CHK1 functionally compromised cells are sensitive to ATR inhibitor. Clonogenic survival of DLD-1, DLD-1 CHK1S317A/, DLD-1 CHK1+/, and DLD-1 ATRS/S
after ATR inhibitor VE-821 treatment is shown. A similar protocol was used as for U2OS and VH-10 cells. Quantitative data: n = 3, mean ± SEM.
(E) Therapeutic efficacy of combined inhibition of ATR and CHK1 in mouse tumor models. Therapeutic efficacy of VX-970 and AZD7762 in H460 lung cancer
xenografted mice is shown. BALB/c nudemice bearing H460 xenograft were divided in four groups (five animals in each group) with a tumor volume of130mm3
in each group. The first control group of animals was treated with vehicle (orally and intraperitoneally). The second group of animals was treated with 25 mg/kg
body weight of CHK1 inhibitor AZD7762 (intraperitoneal route). The third group of animals was treated with 60 mg/kg body weight of ATR inhibitor VE-822 (oral
administration), and the fourth group received a combination of both CHK1 and ATR inhibitors. Vehicle and drugs were administered on days 0–3, 10–12, and
18–20 irrespective of no mice survival in each group. Tumor volume was measured with calipers and is shown here as mean ± SEM. Statistical significance was
determined using two-way ANOVA with repeated measurement (*p < 0.05 and **p < 0.01).
(F) Kaplan-Meier survival curve of H460-xenografted mice. When tumor size reached 1,000 mm3, the animal was sacrificed.
Cell Reports 14, 298–309, January 12, 2016 ª2016 The Authors 301
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Figure 3. ATR andCHK1 Inhibitors, Alone or
in Combination, Decrease Replication Fork
Speed Only in Cancer Cells
(A) Treatment regimen is shown. U2OS and VH-10
cells were treated for 60 min with the indicated
drug concentrations and sequentially labeled with
5-chlorodeoxyuridine (CldU) and 5-iododeoxyur-
idine (IdU) for 30/20 min each in the presence of
the inhibitors. DNA fibers were stained and repli-
cation speed was measured by IdU labeling.
(B and C) Representative images show stained
replication fork tracts for each treatment group.
(D) Quantitative data of replication fork speed
(kb/min), mean ± SEM, and p values were
analyzed with one-way ANOVA for each condition
and cell line.
(E and F) Average distribution of replication fork
rates. A minimum of 450 forks per condition were
analyzed from at least three independent repeats.between the ATR and CHK1 inhibitors in transformed BJ-SV40T
and BJ-RASV12 cells, but not in the non-transformed BJ-hTERT
cells (Figure 2C). These data indicate that the combined inhibi-
tion of ATR and CHK1 is selective against cells with high replica-
tive stress levels, i.e., cancer cells. Importantly, we also carried
out cell viability assays on a larger panel of cancer and normal
cell lines treated for 72 hr with VE-821 and AZD7762 (Figures
S4A–S4J). The drug combination of VE-821 and AZD7762 was
synergistic (combination index [CI] < 1) in all cancer cell lines
tested (U2OS, MCF-7, HCT116WT, HCT116p53/, H460, MX-1,
and HL-60), but not in normal cells, including VH-10 (foreskin
fibroblast), CCD841 (colon epithelial cells), and HUVEC (endo-
thelial cells).
Potentially, the synergy observed between ATR and CHK1
inhibitors could merely result from insufficient inhibition of the
ATR-CHK1 pathway with each compound alone. Alternatively,
this synergy could be caused by the inhibition of both CHK1
and CHK2 by AZD7762. To determine whether there is a genetic
interaction between ATR and CHK1 that could explain the com-
bined activity (as opposed to the two alternatives above), we ex-
ploited DLD-1 cancer cells with one null CHK1 allele and one
allele in which a critical ATR substrate residue on CHK1 has
been mutated (CHK1S317A/) (Wilsker et al., 2008; Zhao and
Piwnica-Worms, 2001). Interestingly, these genetically CHK1-
defective cells were markedly more sensitive to VE-821 than
wild-type control cells, CHK1 heterozygous null DLD-1 cells,
and ATR-deficient (Seckel) DLD-1 cells (ATRs/s) (Figure 2D).
These data clearly demonstrate functionally dead CHK1 cells
(CHK1S317A/) completely rely on ATR activity for survival, and
they suggest that the synthetic lethality observed between VE-
821 and AZD7762 reflects specific synthetic lethality between
ATR and CHK1. In addition, we found that ATR inhibitors syner-
gize with a number of CHK1 inhibitors with varying selectivity302 Cell Reports 14, 298–309, January 12, 2016 ª2016 The Authorsover CHK2, including the highly selective
CHK1 inhibitor SCH-900776 (Figures
S5A–S5G). Importantly, these data
demonstrate a genetic interaction be-
tween CHK1 and the ATR inhibitor VE-
821, rejecting the hypothesis that theobserved synthetic lethal effect is merely a hypomorphic effect
due to increased inhibition of the same activity in the ATR-
CHK1 pathway.
Co-treatment with VX-970 and AZD7762 Extends
Survival in Lung Tumor Mouse Xenograft Models
Wenext further testedourdrugcombination in axenograftmodel.
VX-970 (also referred to as VE-822) is an analog of VE-821 with
excellent ATR selectivity and absorption, distribution, meta-
bolism, and excretion properties that support in vivo studies (Fo-
kas et al., 2012). Mice bearing H460 lung cancer xenografts were
treatedwith 60mg/kgVX-970orally, 25mg/kgAZD7762 intraper-
itoneally, or the combination on days 0–3, 10–12, and 18–20.
While no effect on tumor growth was observed in mice treated
with ATR or CHK1 inhibitor monotherapy, the combined treat-
ment caused a significant reduction in tumor growth (Figure 2E).
Furthermore, combination therapy significantly increased overall
survival (Figure 2F). Importantly, VX-970 and AZD7762 were well
toleratedboth alone and in combination,with nobodyweight loss
observed in the xenograft model (Figure S5H). These data sug-
gest that the combination of ATR and CHK1 inhibitors may pro-
vide an efficacious and well-tolerated anti-cancer therapy.
Combined ATR and CHK1 Inhibition Decreases Fork
Speed Progression in Cancer Cells, Resulting in S Phase
Arrest and Apoptosis
It has been shown previously that inhibition of either ATR or
CHK1 slows down replication fork progression due to an in-
crease in origin firing (Couch et al., 2013; Wilsker et al., 2008).
Consistently, using DNA fiber assay, we found that treatment
of U2OS cells with VE-821 or AZD7762 decreases replication
fork speed (Figure 3). Additionally, fork speed was further
dramatically reduced by combined treatment of U2OS cells
A B
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Figure 4. Combination Treatment of VE-821
and AZD7762 Results in S Phase Arrest in
U2OS Cells
(A) U2OS cells were treatedwith the indicated drug
concentrations for 24 hr and propidium iodide (PI)
staining was carried out to measure cell-cycle
profile using flow cytometry.
(B) Quantitative data were obtained using Modfit
software.
(C) ATR and CHK1 inhibitors in combination
decrease EdU incorporation in U2OS cells. U2OS
cells were treated for 24 hr with the indicated
doses. Images were taken with a confocal micro-
scope and analyzed using ImageJ software. A
mean intensity ofR80 a.u. per cell was considered
as EdU-positive cells. Quantitative data: n = 3,
mean ± SEM.
(D) No significant decrease in EdU incorporation in
normal fibroblast VH-10 cells treated with the ATR
andCHK1 inhibitors either alone or in combination.
VH-10 cells were treated for 24 hr with the indi-
cated doses. Quantitative data: n = 3, mean ±
SEM. Statistical significance was determined us-
ing one-way ANOVA (*p < 0.05, **p < 0.01, and
***p < 0.001).with both agents. In contrast, in VH-10 cells, replication fork pro-
gression speed was unperturbed by these inhibitors, either
alone or in combination. This may indicate that origin firing is un-
affected by ATR or CHK1 inhibition in untransformed cells.
Inhibition of ATR or CHK1 abrogates the G2 DNA damage
checkpoint (Huntoon et al., 2013). We therefore next investi-
gated the effects of VE-821 and AZD7762 on the cell cycle in
U2OS cells. While treatment with either drug alone for 24 hr
had little effect on the cell-cycle profiles, the combination treat-
ment resulted in severe S phase arrest (Figures 4A and 4B).
These results were supported by a significant decrease in EdU
incorporation in U2OS cells treated with VE-821 and AZD7762
in combination, but not alone (Figure 4C). The S phase arrest
and decreased DNA replication are in agreement with replication
fork collapse and the accumulation of DNA damage in cancer
cells co-treated with ATR and CHK1 inhibitors. At later time
points (48–72 hr), the S phase population decreased with a cor-
responding increase in the sub-G1 population, indicating cell
death from replication catastrophe. Cleaved PARP, a marker of
apoptosis, also was detected under these conditions (Figures
S6A–S6C). Taken together, these data demonstrate that com-
bined inhibition of ATR and CHK1 halts replication fork progres-
sion in cancer cells, leading to S phase arrest replication collapse
and the induction of apoptosis. Consistent with our DNA fiber re-
sults, no significant decrease in EdU incorporation was observed
in normal cells treated with VE-821 and AZD7762, suggesting
that the effects of these inhibitors on replication dynamics are
cancer cell specific (Figure 4D).
CDK-Mediated Excess Origin Firing in Cancer Cells
Explains ATR/CHK1 Synthetic Lethality
Phosphorylation of CHK1 by ATR prevents unscheduled origin
firing and replication-induced DNA damage (Feijoo et al.,
2001). However, CHK1 also can be activated by replication
stress through Claspin, which is independent of ATR signalingC(Yang et al., 2008). Thus, there are various ways of activating
CHK1 to prevent replication origin firing. Previously, we demon-
strated that CHK1 inhibition causes overactivation of CDK2-
mediated origin firing and, subsequently, increases replication
stress (Petermann et al., 2010b). We therefore sought to test
if downregulation of replication initiation leads to loss of the
synthetic lethality caused by co-treatment with VE-821 and
AZD7762 in cancer cells.
U2OS cells were pretreated with CDK inhibitor Roscovitine or
CDK/CDC7 inhibitor PHA-767491 (Jones et al., 2013; Petermann
et al., 2010b) prior to the addition of VE-821 and AZD7762 to
downregulate origin firing. Both CDK inhibitors reduced the pan-
nucleargH2AX-positive cell populationmediated by co-treatment
with VE-821 and AZD7762 in a dose-dependent manner, but
increased the gH2AX foci-positive cell population, converting
the irreparable to reparable lesions (Figures 5A, 5B, S7A, S7C,
andS7D).AlthoughCDK inhibitors alonehavenoeffect on replica-
tion fork speed (Jones et al., 2013; Petermann et al., 2010b), both
Roscovitine and PHA-767491 increased replication fork speed in
cells co-treatedwith VE-821 and AZD7762, suggesting alleviation
of replication stress (Figures 5C–5E). Furthermore, Roscovitine
significantly abrogated the synergistic cytotoxic effect of dual
ATR and CHK1 inhibition in U2OS cells (Figures 5F and S7B). No
such enhancement of cell survival was observed with PHA-
767491, but this was attributed to the single agent cytotoxicity of
the compound over prolonged exposures (Figure S7E). Taken
together, these data provide amechanism of action, where inhibi-
tion of both ATR and CHK1 induces an increase in CDK-mediated
origin firing in tumor cells, ultimately leading to RPA exhaustion,
replication catastrophe, and cell death (Figure 5G).
Combined ATR and CHK1 Inhibition Causes Nuclear
Fragmentation in Cancer Cells under Replication Stress
SinceDNA-damagingdrugsarewidelyused incancer therapy,we
investigated whether tumor cells responding to DNA-damagingell Reports 14, 298–309, January 12, 2016 ª2016 The Authors 303
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chemotherapy are more susceptible to the combination of
VE-821 and AZD7762. Within 24 hr, U2OS cells treated with
hydroxyurea (HU), VE-821, and AZD7762 showed a marked
increase in nuclear fragmentation and markers of apoptosis
compared to cells treated with HU alone. (Figures 6A–6C). In
contrast, no increase in nuclear fragmentation was detected
in HU-treated normal cells upon the addition of VE-821 and
AZD7762 (Figure 6D). These data suggest that concurrent inhibi-
tion of ATR and CHK1 may combine productively with DNA-
damaging cancer therapy.
DISCUSSION
Targeting the ATR-CHK1 pathway is a promising strategy for the
treatment of cancer. Only a handful of cancers, such as B cell
lymphomas, are suggested to have sufficiently high endogenous
replication stress to allow the use of ATR or CHK1 inhibitors in
monotherapy (Ho¨glund et al., 2011; Murga et al., 2011). There-
fore, the overwhelming strategy in the clinic is to use the ATR
and CHK1 inhibitors in combination with chemotherapy or radio-
therapy (Brooks et al., 2013; Fokas et al., 2012; Foote et al.,
2013, 2015; Josse´ et al., 2014; Ma et al., 2011; Mitchell et al.,
2010; Tang et al., 2012). In our study, we found that sub-toxic
doses of the ATR inhibitor VE-821 and the CHK1 inhibitor
AZD7762, when combined, show synergistic cytotoxic effects
on cancer cell lines that are relatively insensitive to ATR or
CHK1 inhibitors alone. We believe that this is not merely due to
a hypomorphic effect, as the doses used in this study resulted
in nearly complete inhibition of ATR signaling by VE-821 and
VX-970 and CHK1 signaling by AZD7762, based on our current
and previously published reports. We suggest that this has
important implications for widening the potential scope of ATR
and CHK1 inhibitors beyond monotherapy in tumors harboring
very high levels of replication stress (e.g., B cell lymphomas) or
as combinations with DNA-damaging cytotoxic chemotherapy.
We demonstrate in vivo efficacy with the drug combination in
H460 lung tumor xenograft models (Figures 2E and 2F), without
affecting body weight of the animals. The favorable tolerability
profile is in line with our important observation of no synthetic
lethality between ATR and CHK1 inhibitors in non-transformed
cells. This is an important finding as it suggests that a beneficialFigure 5. Synergistic Cytotoxic Effect in U2OS Cancer Cells by Combin
Excess Origin Firing
(A) U2OS cells were pretreated with the indicated concentrations of the CDK inhib
Cells were probed with anti-phospho (Serine 139) H2AX antibody and anti-53BP
(B) Quantitative data of pan-nuclear gH2AX are shown (mean ± SEM from two in
(C) Treatment regimen for DNA fiber assay in U2OS cells is shown.
(D) CDK inhibitors Roscovitine and PHA-767491 enhance the replication fork spee
were pre-treated with Roscovitine or PHA-767491 for 1 hr prior to the addition o
tracts for each treatment group.
(E) Average distribution of replication fork rates. A minimum of 450 forks per con
(F) Roscovitine abolishes the synergistic cytotoxic effect of combination treatme
treated with VE-821, AZD7762, or the combination with our without Roscovitine f
using resazurin at 72 hr.
(G) Model for ATR/CHK1 synthetic lethality. CHK1 is activated by replication stre
suppress replication stress in cancer, promoting restart and survival. CHK1 inh
replication stress and accumulation of stalled replication forks, requiring ATR ac
presence of both ATR and CHK1 inhibitors.
Ctherapeutic index might be achieved when combining ATR and
CHK1 inhibitors in the clinic. More work is now warranted to
find candidate biomarkers that might enable prospective identi-
fication of cancer patients that will benefit the most from dual
ATR and CHK1 inhibition.
Here we show that oncogene-deregulated CDK activity is
required to manifest the ATR/CHK1 synthetic lethality. In our
model, we propose that CHK1 inhibitors increase overall CDK-
mediated replication stress by increased origin firing, which
in turn likely depletes the limited dinucleotide triphosphate
(dNTP) pool (Bester et al., 2011), resulting in slow or stalled
DNA replication (Alexandrov et al., 2013). This generates an
increasing amount of ssDNA tracts that are protected by an
ATR-mediated supply of RPA to prevent stalled forks from
collapsing (Brooks et al., 2013; Gagou et al., 2010; Petermann
et al., 2010b; Syljua˚sen et al., 2005; Toledo et al., 2013). In the
additional presence of ATR inhibitors, the high number of stalled
replication forks collapses into toxic, irreparable DSBs, killing the
cancer cells. Intuitively, onewould not expect inhibitors of CHK1,
acting downstream of ATR, to have any synergistic effect with
ATR inhibitors. There is, however, much crosstalk in the DNA
damage response network, and CHK1 also is activated by Clas-
pin following replication stress, independently of ATR (Yang
et al., 2008). Also, there is an ATR-dependent, CHK1-indepen-
dent, intra-S phase checkpoint that suppresses origin firing
(Couch et al., 2013; Luciani et al., 2004). ATR and CHK1 also
have distinct functions and may not act linearly in the kinase
cascade (Buisson et al., 2015). This underscores the importance
of CHK1 in preventing origin firing upon replication stress and a
separate role for ATR in preserving replication fork integrity to
prevent collapse (Toledo et al., 2013; Figure 5G). The model pre-
dicts that CHK1 inhibitor monotherapy may be limited in many
cancers due to ATR activation, which will prevent fork collapse
and cell death. Similarly, effective ATR-independent suppres-
sion of CDK activity by CHK1 could limit the efficacy of ATR
monotherapy.
In conclusion, we exemplify a cancer-specific synthetic
lethality between the ATR and CHK1 kinase activities, demon-
strating that it is possible to obtain synthetic lethality between
two proteins within the same pathway. Furthermore, our findings
may have important medical implications by raising the prospectation Treatment of AZD7762/VE-821 Is Mainly Due to CDK-Mediated
itor Roscovitine for 1 hr prior to the addition of VE-821 and AZD7762 for 24 hr.
1, and DNA was counterstained with ToPro.
dependent experiments).
d of U2OS cells treated with VE-821 and AZD7762 in combination. U2OS cells
f VE-821 and AZD7762. Representative images show stained replication fork
dition were analyzed from at least three independent repeats.
nt of AZD7762 and VE-821 in U2OS cancer cells. U2OS cells were individually
or 24 hr, followed by recovery for another 48 hr. Cell viability was measured by
ss both by ATR-dependent and -independent pathways (Yang et al., 2008) to
ibitors increase oncogene-activated CDK activity and origin firing, leading to
tivity to prevent replication collapse. Red arrows indicate primary route in the
ell Reports 14, 298–309, January 12, 2016 ª2016 The Authors 305
A VE-821
c-PARP
s-10 H3
β-actin
VE-8210 0 0 10 10 10
AZD77620 60 120 0 60 120
HU 2 mM+ + + + + +
μM
nM
C
le
av
ed
 
ca
sp
as
e 
3
β-
ac
tin
To
P
ro
M
er
ge
+ + + + ++HU 2 mM
AZD7762
-
-
--
30 60 -
10
30
10
60
10 μM
nM
2
4
6
8
Cleaved  caspase-3
- --
30- 60
10 10 10
6030-
μM
nM
+ + + + + +
%
 c
el
ls
0
20
40
60
Fragmented nuclei
- --
30- 60
10 10 10
6030-
VE-821
AZD7762
HU 2 mM + + + + + +
B
D
C
le
av
ed
 
ca
sp
as
e 
3
β-
ac
tin
To
P
ro
M
er
ge
AZD7762
-
-
--
30 60 -
10
30
10
60
10
+ + + + ++
μM
nM
2 mM HU
4 μM Etoposide
C
VE-821
Figure 6. HU-Induced Replication Stress in Combination with VE-821 and AZD7762 Causes Fragmented Nuclei and the Early Onset of
Apoptosis Only in U2OS Cells
(A) U2OS cells were treated for 24 hr with the indicated drug concentrations and stained with anti-cleaved caspase 3 and b-actin antibodies. Representative
confocal images are shown.
(B) Quantitative data of fragmented nuclei and cleaved caspase-3 positive cells presented as mean ± SEM from three independent experiments.
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that ATR and CHK1 inhibitors may be combined to provide a
well-tolerated cancer therapy with the potential to treat a large
proportion of cancer patients.
EXPERIMENTAL PROCEDURES
Please refer to the Supplemental Experimental Procedures for additional
experimental details.
Cell Lines
U2OS (human bone osteosarcoma cells); VH-10 (human foreskin fibroblast
cells); MCF-7 (human breast cancer cells) (ATCC); CCD841 (human colon
epithelial cells) (ATCC); HA1EB-GFP (GFP-expressing HA1EB, human immor-
talized kidney epithelial cells); HA1EB-GFP-cMYC (GFP-cMYC-expressing
HA1EB cells); and genetically modified cell lines BJ-hTERT (hTERT-immor-
talized BJ cells), BJ-SV40T (SV40T-transformed BJ-hTERT cells), and
BJ-RASV12 (H-RAS V12-transformed BJ-SV40T cells) (Hahn et al., 1999)
were grown in DMEM Glutamax. SW480 (human colorectal adenocarci-
noma) was grown in DMEM. HUVEC (human umbilical endothelial cell);
HCT116WT (human colon carcinoma) (ATCC); HCT116p53/ and DLD-1 (hu-
man colorectal adenocarcinoma); and genetically modified cell lines DLD-1
CHK1S317A/, DLD-1 CHK1+/, and DLD-1 ATRS/S (Wilsker et al., 2008) were
grown in McCoy’s media. MX-1 (human breast carcinoma cells) was grown
in DMEM-F12 and HL-60 was grown in RPMI 1640. The BJ-hTERT, BJ-SV40T,
and BJ-RASV12 cells were generously provided by Dr. Hahn (Dana-Farber
Cancer Institute). HCT116p53/ was also generously provided by Dr. Vogel-
stein (Johns Hopkins University) (Figure S4H). All media were supplemented
with 10% fetal bovine serum (FBS) and 10 U/ml penicillin/streptomycin
(PeSt, Invitrogen), and cells were cultured in 37Cwith 5%CO2. For further de-
tails see the Supplemental Experimental Procedures.
Clonogenic Survival Assay
The 500 (U2OS, MCF-7, DLD-1, DLD-1 CHK1S317A/, DLD-1 CHK1+/, and
DLD-1 ATRS/S) or 1,000 (VH-10) cells were seeded into 10-cm plates. After
5 hr at 37C and 5% CO2, cells were treated with either vehicle (maximum
0.05% DMSO) or various concentrations of inhibitors for ATR (VE-821) and/
or CHK1 (AZD7762) and incubated for 72 hr. After 72 hr, vehicle- and drug-
containing media were replaced with fresh media and further incubated for
5–8 days before fixation and staining with 4% methylene blue in MeOH. Col-
onies were counted manually.
Viability Assay and Drug Interaction
Drug interaction between inhibitor VE-821 and AZD7762 (CI) was determined
using CompuSyn software (version 1.0.1), where CI < 1 indicates synergy,
CI = 1 indicates additivity, and CI > 1 indicates antagonism (Chou, 2010).
For further details see the Supplemental Experimental Procedures.
DNA Fiber Assay
Fiber assay was done as previously described (Groth et al., 2010); for details
see the Supplemental Experimental Procedures.
Microscopy
Confocal images were taken using either an LSM 510 63X or LSM 780
microscope (Zeiss) equipped with a 403 oil objective. For high-throughput mi-
croscopy, a PerkinElmer operetta high-content microscope equipped with a
103 objective was used. For details on microscopy and immunofluorescence
see the Supplemental Experimental Procedures.(C) Western blot showing apoptosis in U2OS cells treated with ATR and CHK1 i
concentrations for 24 hr; lysed; protein extracted; and western blotting was perfo
b-actin antibodies.
(D) HU-induced replication stress does not cause fragmentation of nuclei or apop
in 24 hr. Etoposide treatment (4 mM) was used to induce apoptosis as a positive
CComet Assay
Comet assay was performed as previously described (Gad et al., 2014); for de-
tails see the Supplemental Experimental Procedures.
Cell Cycle-Cell Cycle
Cells (150,000) were seeded in six-well plates and kept for overnight incuba-
tion. The next day, cells were treated with DMSO, VE-821, AZD7762, or the
combination. At the end of 24-, 48-, or 72-hr incubation, the supernatant as
well as the trypsinized single-cell suspension were collected. After washing
twice with cold PBS, cells were fixed in 70% chilled methanol and kept at
20C. On the day of flow cytometry, 400 ml PBS, 50 ml RNaseA (1 mg/ml),
and 5 ml propidium iodide (PI, 400 mg/ml) were added to each tube and there-
after incubated at 37C for 30 min. At the end of the incubation period, the cell
suspension was strained through a 40-mm membrane filter. The sample was
analyzed by using BD FACScalibur, and Modfit software was used to quantify
data.
Western Blotting
For details see the Supplemental Experimental Procedures.
In Vivo Xenograft
Animal experiments were carried out according to the described rules and reg-
ulations of the regional animal ethical committee Stockholm and in compliance
with EU 2010/63 directive. Before conducting experiments, animals were
acclimatized in the animal house for a week with ad libitum food and water,
a 12-hr light cycle, and the temperature and humidity set according to labora-
tory animal guidelines and regulations. Human lung cancer H460 cells
(5 million) in PBS were injected subcutaneously in the flank of 6-week-old
male nude mice. After 8–9 days of implantation, the animals were divided
into four groups based on tumor size, with a mean tumor volume of
130 mm3. The first group received vehicle as follows: 10% D-a-Tocopherol
polyethylene glycol 1000 succinate (Sigma) in water administered via oral
gavage and 11.3% (2-Hydroxy propyl)-b cyclodextrin in saline administered
intraperitoneally. The second group received AZD7762 at 25 mg/kg body
weight, dissolved in 11.3% (2-Hydroxy propyl)-b cyclodextrin in saline via
intraperitoneal administration. The third group received VX-970 via oral gavage
at 60 mg/kg body weight dissolved in 10% D-a-Tocopherol polyethylene gly-
col 1000 succinate in water. The fourth group received both inhibitors. Body
weight and tumor volume (length 3 width 3 width 3 0.52) were measured
twice a week. When tumor volume reached 1,000 mm3, then that particular
mouse was sacrificed and considered as endpoint.
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism 5 software. Unless
indicated, differences were compared using one-way ANOVA.
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